RayStation 7, the latest release of RaySearch’s radiation therapy treatment planning system, adds new functionality and a wide range of improvements. Significant additions include support for Hyperscan technology from Mevion Medical Systems, and integration with RayCare, the next-generation oncology information system (OIS) shortly to be launched by RaySearch.

December 19, 2017 — Humanetics Corp. presented data at the annual meetings of the American Society for Radiation Oncology (ASTRO) and the Radiation Research Society (RRS), on the company’s new drug candidate, BIO 300, which is being evaluated as a potential treatment to prevent erectile dysfunction in patients undergoing radiotherapy for prostate cancer. The annual ASTRO meeting was held Sept. 24-27 in San Diego, and the annual RRS meeting was held Oct.

December 19, 2017 — IBA (Ion Beam Applications SA) announced that Miami Cancer Institute treated its first patients, children with cancer, on IBA’s Proteus Plus proton therapy system.

December 19, 2017 — Toshiba Medical, a Canon Group company, introduced the Galan RT Solutions suite of radiation therapy tools, available on the premium Vantage Galan 3T magnetic resonance imaging (MRI) system at the 2017 Radiological Society of North America (RSNA) Annual Meeting, Nov. 26-Dec. 1 in Chicago.

iCAD Inc. announced the results of a landmark study that showed the benefits of adjunct intraoperative radiation therapy (IORT) compared to external beam radiation therapy (EBRT) in the treatment of early-stage breast cancer. The analysis demonstrated that IORT could result in direct cost savings for the U.S. healthcare system of more than $630 million over the lifetime of patients diagnosed annually with early-stage breast cancer, as well as significantly benefit patient health by minimizing radiation exposure and offering a better quality of life. The results of the study, which were originally published in the peer-reviewed Cost Effectiveness and Resource Allocation, determined IORT to be the preferred method of treatment.

The FDA issued new warnings on MRI gadolinium contrast agents. (GBCAs)

The U.S. Food and Drug Administration (FDA) announced in a new drug safety communication is this week that it is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) used for magnetic resonance imaging (MRI). This includes increased patient education and requiring gadolinium contrast vendors to conduct additional animal and clinical studies to assess the safety of these agents.

Radiological and Diagnostic Imaging Society of Sao Paulo

Society for Pediatric Radiology (SPR)

Building a Bridge Between Radiology and Orthopaedics

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now